Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

NCT03332017 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03332017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03332017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
November 14, 2017
Completion date
December 27, 2024
Enrollment
217 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory follicular non-hodgkin lymphoma